Articles from Mammoth Biosciences, Inc.

Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation in vivo CRISPR gene editing platform to create potential one-time curative therapies, today announced its participation in the upcoming 44th Annual J.P. Morgan Healthcare Conference.

Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation in vivo CRISPR gene editing platform to create potential one-time curative therapies, today announced new preclinical data on its first clinical development candidate, MB-111, to be presented at the European Society of Gene & Cell Therapy (ESGCT) 32nd Annual Congress in Seville, Spain, on October 8, 2025.

Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation CRISPR gene editing platform to create potential one-time curative therapies, today announced that Renan Sper, DVM, Ph.D., principal scientist, preclinical therapeutics at Mammoth, will present new preclinical data at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting in New Orleans, May 13-17, 2025.

Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation CRISPR gene editing platform to create potential one-time curative therapies, today announced new preclinical research, published on the preprint server bioRxiv, that establishes proof-of-concept of NanoCas™, the first ultracompact CRISPR system capable of efficient extrahepatic editing when delivered systemically using a single adeno-associated viral (AAV) vector.

Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation CRISPR gene-editing platform to create potential one-time curative therapies, today announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference.

Mammoth Biosciences, a biotechnology company harnessing its proprietary next-generation CRISPR platform to create potential one-time curative therapies, today announced Janice Chen, Ph.D., chief technology officer and co-founder of Mammoth, will present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles, CA, May 16 - 20, 2023.

Mammoth Biosciences, Inc., a biotechnology company building the next generation of CRISPR products with a mission to cure and detect diseases, today announced its participation in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Mammoth Biosciences, Inc., a biotechnology company building the next generation of CRISPR products with a mission to cure and detect diseases, today announced the appointment of Phil Tinmouth as Chief Business Officer and Siang Chin as General Counsel.

Mammoth Biosciences, Inc., a biotech company harnessing next-generation CRISPR technology to cure and detect disease, today announced that it has been named to Fast Company’s 2022 Next Big Things in Tech list, honoring the technology breakthroughs that promise to shape the future of their industries. Mammoth was recognized for the transformative impact of its ultracompact CRISPR systems on human health.

Mammoth Biosciences, Inc., a biotech company harnessing next-generation CRISPR technology to cure and detect disease, today announced its recognition as a BioSpace 2023 Best Place to Work in the small employer category, a testament to the company’s continuous commitment to its employees, culture, and mission.

Mammoth Biosciences, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its DETECTR BOOST® SARS-CoV-2 Reagent Kit, a first of its kind high-throughput solution that combines the power of CRISPR with laboratory automation for SARS-CoV-2 testing.

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies.